BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Rides Deal Wave to Stock Bump

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, is riding a wave that pushed its stock up 20% with no DRIO-related news. An article published to MarketWatch today titled, “UPDATE: Teladoc and Livongo Health to merge in deal valued at $18.5 billion,” covers a move amid a trend toward virtual healthcare that places DRIO, a provider of digital health solutions, in the right place at the right time. The article reads, “Teladoc Health Inc. (NYSE: TDOC) and Livongo Health Inc. (NASDAQ: LVGO) said Wednesday they have agreed to merge in a deal valued at $18.5 billion to create a company that can serve a spectrum of health needs, using virtual care. Under the terms of the deal, Livongo shareholders will receive 0.592x shares of Teladoc plus $11.33 in cash per share owned. Teladoc shareholders will own about 58% of the combined entity, while Livongo shareholders will own the remaining 42%. The combination ‘creates a global leader in consumer centered virtual care,’ the companies said in a joint statement. The new entity is expected to have pro forma revenue of about $1.3 billion for 2020, equal to pro forma growth of 85%.”

To view the full press release, visit http://ibn.fm/IB93S

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Its cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, visit  www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Data Demonstrating Two-Year Stability of ThermoVax Ebolavirus Vaccines

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the publication of…

4 hours ago

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Preclinical Data Showing CNM-Au8 Improves Cellular Health in Parkinson’s Disease Model 

Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc., announced new preclinical data…

5 hours ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights CEO Dr. Vuong Trieu’s Impact and Clinical Pipeline Progress

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing oncology and immunotherapy treatments, provided an…

6 hours ago

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Subsidiary Publishes Landmark Primer on Oncology Real-World Evidence

Fifty 1 Labs (OTC: FITY) through its subsidiary Fifty1 AI Labs, announced the publication of…

7 hours ago

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) CEO Featured on IBN’s BioMedWire Podcast

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing the IzoView Breast…

8 hours ago

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures $5.3 Million from Warrant Exercises to Advance AVERSA Fentanyl NDA

Nutriband (NASDAQ: NTRB), a company developing abuse deterrent pharmaceutical products, announced the exercise of warrants…

8 hours ago